$ALEC
Alector Inc Stock $alec

$alec Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000095017022014810 Filed on August 04, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$14.85M	$79.85M	$24.47M
YoY Change	-91.86%	1115.76%	495.47%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$14.25M	$15.84M	$15.55M
YoY Change	9.48%	12.55%	41.27%
% of Gross Profit
Research & Development	$48.35M	$54.53M	$53.04M
YoY Change	12.26%	14.04%	15.98%
% of Gross Profit
Depreciation & Amortization	$1.347M	$1.384M	$1.589M
YoY Change	-16.07%	-15.09%	5.93%
% of Gross Profit
Operating Expenses	$62.60M	$70.38M	$68.60M
YoY Change	11.62%	13.71%	20.89%
Operating Profit	-$47.75M	$9.475M	-$44.12M
YoY Change	-137.8%	-117.13%	-16.17%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$2.333M	$1.450M	$264.0K
YoY Change	770.52%	714.61%	-43.1%
Pretax Income	-$45.42M	$10.93M	-$43.86M
YoY Change	-135.87%	-119.81%	-15.93%
Income Tax	$733.0K	$1.042M	$758.0K
% Of Pretax Income		9.54%
Net Earnings	-$46.15M	$9.883M	-$44.62M
YoY Change	-136.45%	-117.92%	-14.48%
Net Earnings / Revenue	-310.72%	12.38%	-182.3%
Basic Earnings Per Share	-$0.56	$0.12	-$0.54
Diluted Earnings Per Share	-$0.56	$0.12	-$543.4K
COMMON SHARES
Basic Shares Outstanding	82.56M	82.39M	82.04M
Diluted Shares Outstanding	82.60M	82.59M	82.10M

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$758.3M	$808.9M	$868.6M
YoY Change	-2.51%	153.11%	139.47%
Cash & Equivalents	$184.2M	$172.3M	$454.6M
Short-Term Investments	$574.1M	$636.6M	$414.0M
Other Short-Term Assets	$10.17M	$9.350M	$9.536M
YoY Change	18.42%	-4.2%	-20.53%
Inventory
Prepaid Expenses
Receivables	$6.491M	$8.816M	$12.82M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$775.0M	$827.0M	$890.9M
YoY Change	-1.66%	151.12%	137.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$26.29M	$26.03M	$26.23M
YoY Change	-5.77%	-9.29%	-11.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.784M	$5.919M	$5.932M
YoY Change	1.19%	-1.23%	44.68%
Total Long-Term Assets	$62.08M	$62.65M	$63.53M
YoY Change	-6.24%	-7.57%	-3.25%
TOTAL ASSETS
Total Short-Term Assets	$775.0M	$827.0M	$890.9M
Total Long-Term Assets	$62.08M	$62.65M	$63.53M
Total Assets	$837.0M	$889.7M	$954.5M
YoY Change	-2.01%	124.03%	116.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.546M	$4.646M	$6.752M
YoY Change	94.19%	-61.1%	27.4%
Accrued Expenses	$23.23M	$23.71M	$20.04M
YoY Change	12.82%	7.26%	-44.48%
Deferred Revenue	$119.7M	$107.0M	$95.61M
YoY Change	26.4%	320.95%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$160.9M	$149.4M	$142.9M
YoY Change	21.14%	100.84%	122.9%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$233.0K	$233.0K	$158.0K
YoY Change	47.47%	47.47%	-99.89%
Total Long-Term Liabilities	$233.0K	$233.0K	$158.0K
YoY Change	47.47%	47.47%	-99.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$160.9M	$149.4M	$142.9M
Total Long-Term Liabilities	$233.0K	$233.0K	$158.0K
Total Liabilities	$583.9M	$601.2M	$686.9M
YoY Change	12.66%	182.77%	223.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$527.3M	-$481.1M	-$491.0M
YoY Change	34.93%	-7.01%	6.23%
Common Stock	$8.000K	$8.000K	$8.000K
YoY Change	0.0%	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$253.1M	$288.5M	$267.5M
YoY Change
Total Liabilities & Shareholders Equity	$837.0M	$889.7M	$954.5M
YoY Change	-2.01%	124.03%	116.74%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$46.15M	$9.883M	-$44.62M
YoY Change	-136.45%	-117.92%	-14.48%
Depreciation, Depletion And Amortization	$1.347M	$1.384M	$1.589M
YoY Change	-16.07%	-15.09%	5.93%
Cash From Operating Activities	-$49.05M	-$57.44M	$135.1M
YoY Change	-111.02%	28.98%	-356.37%
INVESTING ACTIVITIES
Capital Expenditures	-$1.915M	-$744.0K	$692.0K
YoY Change	109.29%	-14.97%	-26.93%
Acquisitions
YoY Change
Other Investing Activities	$62.44M	-$225.1M	-$11.41M
YoY Change	-191.64%	-491.99%	-110.33%
Cash From Investing Activities	$60.53M	-$225.8M	-$12.11M
YoY Change	-187.66%	-499.37%	-111.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	489.0K	906.0K	2.483M
YoY Change	-96.7%	-69.14%	-35.91%
NET CHANGE
Cash From Operating Activities	-49.05M	-57.44M	135.1M
Cash From Investing Activities	60.53M	-225.8M	-12.11M
Cash From Financing Activities	489.0K	906.0K	2.483M
Net Change In Cash	11.97M	-282.4M	125.5M
YoY Change	-96.94%	-1989.42%	106.59%
FREE CASH FLOW
Cash From Operating Activities	-$49.05M	-$57.44M	$135.1M
Capital Expenditures	-$1.915M	-$744.0K	$692.0K
Free Cash Flow	-$47.14M	-$56.70M	$134.4M
YoY Change	-110.57%	29.86%	-350.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021Q2	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://alector.com/20220630#CollaborationRevenueMember
	dei	Amendment Flag AmendmentFlag	false
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q2	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://alector.com/20220630#CollaborationRevenueMember
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001653087
	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://alector.com/20220630#CollaborationRevenueMember
	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://alector.com/20220630#CollaborationRevenueMember
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38792
	dei	Entity Registrant Name EntityRegistrantName	Alector, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2933343
	dei	Entity Address Address Line1 EntityAddressAddressLine1	131 Oyster Point Blvd
	dei	City Area Code CityAreaCode	415
	dei	Trading Symbol TradingSymbol	ALEC
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 600
	dei	Local Phone Number LocalPhoneNumber	231-5660
	dei	Security12b Title Security12bTitle	Common Stock
CY2022Q2	alec	Collaboration Receivable CollaborationReceivable	8816000
CY2021Q4	alec	Collaboration Receivable CollaborationReceivable	7391000
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9350000
	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	82563921
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	172265000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	329152000
CY2022Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	636590000
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	406099000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7071000
CY2022Q2	us-gaap	Assets Current AssetsCurrent	827021000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	749713000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26034000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27330000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	29226000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	30569000
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1472000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1472000
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5919000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5574000
CY2022Q2	us-gaap	Assets Assets	889672000
CY2021Q4	us-gaap	Assets Assets	814658000
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4646000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4749000
CY2022Q2	alec	Accrued Clinical Supply Cost AccruedClinicalSupplyCost	6142000
CY2021Q4	alec	Accrued Clinical Supply Cost AccruedClinicalSupplyCost	8748000
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23705000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	27460000
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	106994000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	90803000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7922000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7795000
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	149409000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	139555000
CY2022Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	413899000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	334415000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	37615000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	345000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	39806000
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	233000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	158000
CY2022Q2	us-gaap	Liabilities Liabilities	601156000
CY2021Q4	us-gaap	Liabilities Liabilities	513934000
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	82544901
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	82544901
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	81986192
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	81986192
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	8000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	8000
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	775843000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	748036000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6224000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-943000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-481111000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-446377000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	288516000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	300724000
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	889672000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	814658000
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	79851000
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6568000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	104325000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10678000
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	54534000
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47818000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	107577000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	93551000
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15842000
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14075000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31396000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25087000
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	70376000
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	61893000
	us-gaap	Operating Expenses OperatingExpenses	138973000
	us-gaap	Operating Expenses OperatingExpenses	118638000
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	9475000
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-55325000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-34648000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-107960000
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1450000
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	178000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1714000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	642000
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	10925000
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3376000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-55147000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-32934000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-107318000
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1042000
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1800000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	9883000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-55147000
	us-gaap	Net Income Loss NetIncomeLoss	-34734000
	us-gaap	Net Income Loss NetIncomeLoss	-107318000
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-2289000
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-207000
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-5281000
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-411000
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	7594000
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55354000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40015000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-107729000
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.12
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.35
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.12
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.35
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82394784
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	79790036
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82248880
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	79598188
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	82588368
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	79790036
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	82248880
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	79598188
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	300724000
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2483000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11939000
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2992000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-44617000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	267537000
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	41000
CY2022Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	866000
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12478000
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2289000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	9883000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	288516000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	267530000
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3874000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8800000
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-204000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-52171000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	227829000
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1993000
CY2021Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	969000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9078000
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-207000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-55147000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	184515000
	us-gaap	Profit Loss ProfitLoss	-34734000
	us-gaap	Profit Loss ProfitLoss	-107318000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2973000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3130000
	us-gaap	Share Based Compensation ShareBasedCompensation	24417000
	us-gaap	Share Based Compensation ShareBasedCompensation	17878000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-718000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1152000
	alec	Amortization Right Of Use Asset AmortizationRightOfUseAsset	1343000
	alec	Amortization Right Of Use Asset AmortizationRightOfUseAsset	938000
	alec	Increase Decrease In Collaboration Receivable IncreaseDecreaseInCollaborationReceivable	1425000
	alec	Increase Decrease In Collaboration Receivable IncreaseDecreaseInCollaborationReceivable	0
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2279000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1557000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-530000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	9148000
	alec	Increase Decrease In Accrued Liabilities And Accrued Clinical Supply Costs IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts	-6175000
	alec	Increase Decrease In Accrued Liabilities And Accrued Clinical Supply Costs IncreaseDecreaseInAccruedLiabilitiesAndAccruedClinicalSupplyCosts	-4225000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	95675000
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-10678000
	alec	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-2064000
	alec	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-2014000
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	75000
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-314000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	77649000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-97236000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1436000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1775000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	321290000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	5081000
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	84801000
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	173000000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-237925000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	166144000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2524000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-156887000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5867000
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	865000
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	969000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3389000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6836000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	75744000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	330624000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51441000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	173737000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	127185000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	945000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	348000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expense during the reporting period. The Company evaluates its estimates, including those related to revenue recognition, manufacturing accruals, clinical accruals, fair value of assets and liabilities, income taxes uncertainties, stock-based compensation, and related assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.</span>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and short-term marketable securities. Cash and cash equivalents are deposited in checking and sweep accounts at financial institutions. Such deposits may, at times, exceed federally insured limits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	127185000
CY2022Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	683000000.0
CY2022Q2	alec	Available For Sale Securities Debt Maturities Within One Through Two Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneThroughTwoYearFairValue	74300000
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	465400000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	172265000
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	125713000
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1472000
CY2021Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1472000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	173737000
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	307900
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12478000
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9078000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24417000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17878000
CY2021Q2	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.013
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.012
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	9883000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-55147000
	us-gaap	Net Income Loss NetIncomeLoss	-34734000
	us-gaap	Net Income Loss NetIncomeLoss	-107318000
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82394784
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	79790036
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82248880
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	79598188
CY2022Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	193584
CY2021Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	0
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	82588368
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	79790036
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	82248880
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	79598188
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.12
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.35
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.12
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.35
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14084153
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13558443
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15202999
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13558443

Files In Submission

Name	View Source	Status
0000950170-22-014810-index-headers.html	Edgar Link	pending
0000950170-22-014810-index.html	Edgar Link	pending
0000950170-22-014810.txt	Edgar Link	pending
0000950170-22-014810-xbrl.zip	Edgar Link	pending
alec-20220630.htm	Edgar Link	pending
alec-20220630.xsd	Edgar Link	pending
alec-20220630_cal.xml	Edgar Link	unprocessable
alec-20220630_def.xml	Edgar Link	unprocessable
alec-20220630_htm.xml	Edgar Link	completed
alec-20220630_lab.xml	Edgar Link	unprocessable
alec-20220630_pre.xml	Edgar Link	unprocessable
alec-ex31_1.htm	Edgar Link	pending
alec-ex31_2.htm	Edgar Link	pending
alec-ex32_1.htm	Edgar Link	pending
alec-ex32_2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALEC
Alector Inc Stock $alec

2022 Q3 Form 10-Q Financial Statement

#000095017022014810 Filed on August 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALEC Alector Inc Stock $alec

2022 Q3 Form 10-Q Financial Statement

#000095017022014810 Filed on August 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALEC
Alector Inc Stock $alec